Effect of a killer toxin of Pichia anomala to Pneumocystis. Perspectives in the control of pneumocystosis.
Despite the development of drugs in the prophylaxis of pneumocystosis, Pneumocystis carinii remains a major opportunistic microorganism in immunosuppressed individuals, especially in human immunodeficiency virus-infected patients. Since side effects were frequently observed after administration of trimethoprim-sulfamethoxazole or pentamidine, the drugs which are mainly used in treating human P. carinii pneumonia (PCP), new therapeutic strategies should be developed. Over the last years, the inhibitory effect of a Pichia anomala killer toxin (PaKT), a molecule with a wide spectrum of antimicrobial activity, was characterized on P. carinii. The susceptibility of mouse and rat-derived Pneumocystis to PaKT has been demonstrated by in vitro attachment tests and in vivo infectivity assays. Nevertheless, PaKT is strongly antigenic, toxic and could not be used directly as a therapeutic agent. Then, a new strategy using killer toxin-like anti-idiotypic antibodies (KT-antiIds) mimicking the fungal toxin activity has been developed. Different KT-antiIds were obtained by idiotypic immunization with a monoclonal antibody (mabKT4). This mabKT4 neutralized the killer properties of the PaKT. KT-antiIds were produced by immunization against the variable domain (idiotype) of mAbKT4 (internal image of the killer toxin receptor), or they were obtained directly from vaginal fluid of patients affected by recurrent vaginal candidiosis. In this last case, such natural KT-antiIds were immunopurified by affinity-chromatography with mAbKT4 and their anti-P. carinii activity was then evaluated. Our results showed that both the in vitro attachment of rat-derived parasites and their infectivity to nude rats were inhibited by the KT-antiIds. With regard to KT-antiIds obtained by immunization, the antimicrobial activity of a monoclonal KT-antiIds (mAbK10) has been evaluated by using a PCP experimental nude rat model treated by mAbK10 administered by aerosol. The pneumocystosis extension was significantly reduced in this model. The monoclonal KT-antiIds were effective against P. carinii in reducing parasite proliferation in lungs of nude rats. Further experiments are in progress to study the in vivo anti-P. carinii activity of KT-antiIds by using recombinant single-chain of the variable fragment of KT-antiIds. Yeast killer toxin-like recombinant molecules could provide the basis for a new therapeutic strategy towards the control of pneumocystosis.
Séguy
N
N
Dépt. Microbiol. Ecosystèmes, Institut Pasteur de Lille, France. nathalie.seguy@pasteur-lille.fr
Polonelli
L
L
Dei-Cas
E
E
Cailliez
J C
JC
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D000908:Antibodies, Fungal / Q000276:immunology; D006801:Humans; D055646:Killer Factors, Yeast; D009183:Mycotoxins / Q000235:genetics / Q000494:pharmacology*; D010843:Pichia; D011010:Pneumocystis / Q000187:drug effects; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000494:pharmacology
D000888:Antibodies, Anti-Idiotypic; D000908:Antibodies, Fungal; D055646:Killer Factors, Yeast; D009183:Mycotoxins; D011994:Recombinant Proteins; C087906:killer toxin, Pichia